Acadian Asset Management LLC Harpoon Therapeutics, Inc. Transaction History

Acadian Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$0.55 - $0.82 $20,345 - $30,333	-36,992 Reduced 32.53%	76,710 $53,000
Q1 2023 May 11, 2023	SELL	$0.65 - $1.37 $8,613 - $18,155	-13,252 Reduced 10.44%	113,702 $84,000
Q4 2022 Feb 14, 2023	BUY	$0.6 - $1.41 $42,191 - $99,149	70,319 Added 124.16%	126,954 $91,000
Q2 2022 Aug 09, 2022	BUY	$1.78 - $5.02 $100,810 - $284,307	56,635 New	56,635 $109,000
Q3 2021 Nov 12, 2021	SELL	$7.88 - $14.0 $180,712 - $321,062	-22,933 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$13.81 - $23.25 $360,896 - $607,592	-26,133 Reduced 53.26%	22,933 $318,000
Q1 2021 May 11, 2021	BUY	$17.65 - $24.16 $231,179 - $316,447	13,098 Added 36.42%	49,066 $1.03 Million
Q4 2020 Feb 11, 2021	BUY	$12.83 - $17.84 $208,692 - $290,185	16,266 Added 82.56%	35,968 $598,000
Q3 2020 Nov 09, 2020	SELL	$11.01 - $18.52 $31,851 - $53,578	-2,893 Reduced 12.8%	19,702 $334,000
Q2 2020 Aug 12, 2020	BUY	$11.11 - $24.72 $164,305 - $365,584	14,789 Added 189.46%	22,595 $375,000
Q1 2020 May 11, 2020	BUY	$10.74 - $16.32 $83,836 - $127,393	7,806 New	7,806 $90,000

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.